Cervical Cancer Clinical Trials in Nanchang, Jiangxi
3 recruitingNanchang, Jiangxi, China
Showing 1–3 of 3 trials
Recruiting
Phase 3
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
Cervical Cancer
Merck Sharp & Dohme LLC686 enrolled239 locationsNCT06459180
Recruiting
Protein Molecular Characteristics and Prognosis of Cervical Neuroendocrine Tumors
Cervical CancerNeuroendocrine NeoplasmWomen+2 more
Fujian Maternity and Child Health Hospital300 enrolled9 locationsNCT06276309
Recruiting
Phase 2
A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer
Cervical Cancer
RemeGen Co., Ltd.116 enrolled12 locationsNCT06155396